Navigation Links
Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies
Date:7/15/2009

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an evaluation and option agreement in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins.

The agreement with CII provides Morphotek access to several of CII's monoclonal antibodies. Morphotek will evaluate one or more of the antibodies and have the right to exercise an option for a license during the evaluation period. Should Morphotek choose to exercise its option, the parties will enter negotiations for a license under which Morphotek would receive an exclusive worldwide license to develop the antibodies for potential therapeutic, diagnostic and prophylactic use, and would retain the responsibility for the commercialization of the antibodies.

"We are delighted that CII has decided to partner with Morphotek," said Nicholas C. Nicolaides, Ph.D., President and CEO of Morphotek. "We believe that these antibodies provide a novel approach to targeting tumor-associated proteins. Antibody targeting of tumor-associated proteins has demonstrated promising anti-angiogenic activity in preclinical studies. We are pleased to be able to access these antibodies for evaluation and possible development as we continue to grow our therapeutic antibody portfolio."

"CII has developed several monoclonal antibodies, peptides and small molecules with potential applications in the treatment of cancer and neo-vascular disorders," said Toni Gray, President and CEO of CII. "This agreement with Morphotek has the potential for the development of new drug candidates for cancer."

Morphotek will apply its antibody discovery technologies, including its pro
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Insero Health, Inc., a company developing natural compounds to ... disorders, is today reporting top-line results from a Phase ... with drug-resistant epilepsy.  The data are being presented at ... by Dr. Steven Schachter , Harvard ... Board.  In this study, INS001 appeared safe and well ...
(Date:5/17/2013)... CA (PRWEB) May 17, 2013 IAC Industries ... Technologies, a start up laboratory needing to set up and ... moving to a larger facility within a year’s time. How ... knowledge that the laboratory is temporary? What is efficient and ... Series modular workstations from IAC Industries. The planners at DisperSol ...
(Date:5/16/2013)... May 16, 2013 In late 2012, Dr. ... speak to doctors in China about Appearance Medicine . ... this was her first trip to lecture in China, and ... Guangzhou and Fuzhou, home to 12 and 7 million people ... very high at this point in time. As Dr. Hart ...
(Date:5/16/2013)... -- The registration deadline has been extended until May 22 ... Conference, the premier conference for bioscience financial officers. The ... San Diego Bayfront. "We are putting ... to make sure as many people as possible have ... , Chief Financial Officer of Mast Therapeutics, Inc. ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... . , What would be a case for ... for a micro engine. If it sputters, this is caused ... with its running. Researchers at the University of Stuttgart and ... observed this with a heat engine on the micrometre scale. ...
... Dec. 12, 2011  Kensey Nash Corporation (Nasdaq: ... by Spectranetics Corporation (Nasdaq: SPNC ) that ... of the endovascular product lines purchased from Kensey Nash ... $6 million milestone payable to Kensey Nash.  As previously ...
... 12, 2011  Fox Insurance Company, a Medicare Part D ... judgment in the arbitration between the company and ProCare, ... million, following a suit against ProCare based on Fox,s ... Nathan M. Barotz, chairman of Fox Insurance Company ...
Cached Biology Technology:The world's smallest steam engine 2The world's smallest steam engine 3Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager 2
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... (ENDO) 95th Annual Meeting in San Francisco, CA ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... -- Injectable nanoparticles developed at MIT may someday ... diabetes to constantly monitor their blood-sugar levels and ... designed to sense glucose levels in the body ... insulin, thereby replacing the function of pancreatic islet ... 1 diabetes. Ultimately, this type of system could ...
(Date:5/16/2013)... ancient extinct creature with ,scissor hand-like, claws in fossil ... favourite movie star. , The 505 million year ... depp-eye), which is a distant ancestor of lobsters and ... his starring role as Edward Scissorhands - a movie ... who has scissors for hands. , Kooteninchela ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2
... to seeing Garfield-sized cats, obese, middle-aged cats can have ... be fatal. The causes of diabetes mellitus in cats ... about whether a dry food diet puts cats at ... University of Missouri-Columbia veterinarian suggests that weight gain, not ...
... over-the-counter product for topical wound care is more effective ... MRSA, which is potentially deadly and in recent years ... much broader public concern. A new laboratory study ... a product made with benzethonium chloride kills common types ...
... team of researchers from the Wellman Center for Photomedicine at ... developed an optical device that allows them to peer through ... through its bloodstream. In the Dec. 1 issue ... of America, the team describes how they used the device, ...
Cached Biology News:Choosing dry or wet food for cats makes little difference 2Best treatment identified to reduce deadly Staph infections 2Best treatment identified to reduce deadly Staph infections 3Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream 2Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream 3
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Biology Products: